Clinical Trial to study the effectiveness of Dupilumab on AERD

Trial ID:
IRB-23-8183
Andrew A. White, M.D.

Inclusion Criteria

Patients must:

  • Be, at least, 18 years old.
    Have a known history of nasal polyposis.
    Be currently prescribed and taking dupilumab 300mg subcutaneously every 2 weeks for nasal polyposis or eosinophilic asthma.

Exclusion Criteria

Patients must not:

  • Have a history of gastrointestinal reactions during NSAID triggered events.

    Have unstable asthma or history of severe reactions during previous desensitization attempts.
    Be unable to take montelukast.
    Have a history of gastrointestinal bleeding or a bleeding disorder.
    Be pregnant.
    Have used an asthma biologic, other than dupilumab, in the past 3 months.
    Have recently needed systemic corticosteroids to stabilize their asthma.
    Have had any sinus surgery in the previous 4 weeks.

Additional Info

All study visits will occur at Scripps Clinic Carmel Valley. Study visits will include pulmonary testing and an aspirin desensitization/challenge. The aspirin desensitization will last 1 to 2 days (approximately 8 hours per day).

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org